LMP2A | germinal center | plasma cell differentiation | B cells | autoimmune diseases E pstein-Barr virus (EBV) is a B-lymphotropic human herpesvirus associated with a variety of hematopoietic cancers, including endemic Burkitt lymphoma, Hodgkin lymphoma, lymphoproliferative disorders in immune-compromised people, nasopharyngeal carcinoma, and some gastric cancers (1, 2) . Nevertheless, EBV establishes lifelong latent infection by adolescence in more than 95% of adults worldwide. EBV efficiently infects resting human B cells in vitro, leading to their activation and proliferation. EBVinfected B cells grow in vitro as immortalized lymphoblastoid cell lines (LCL). LCLs express EBV-encoded proteins including the EBV nuclear antigens (EBNAs) EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNALP and the latent membrane proteins LMP1, LMP2A, and LMP2B. Of these EBV gene products, EBNA2, EBNALP, EBNA3A, EBNA3C, and LMP1 are essential for B-cell transformation (3), whereas EBNA1 is necessary for EBV episome persistence (4) .
LMP2A consists of an N-terminal cytoplasmic domain, 12 membrane-spanning domains, and a short C-terminal cytoplasmic domain. The N-terminal cytoplasmic domain has an immune receptor tyrosine-based activation motif (ITAM), which can recruit the protein tyrosine kinases Syk and Src (5) . In LCLs or mouse cells that ectopically express LMP2A, LMP2A suppresses B-cell antigen receptor (BCR) signaling (6) (7) (8) . In mice lacking BCR expression, transgenic LMP2A can partially rescue B-cell differentiation (9) (10) (11) , indicating that LMP2A can mimic tonic BCR signals necessary for B-cell survival in vivo (12) . Likewise, LMP2A is essential for growth transformation of germinal center (GC)-derived BCR − B cells (13) . Depending on its B-cell expression level in murine models, constitutive LMP2A expression alters B-cell development or augments the differentiation and activation of antigen-driven B cells (9, 10, (14) (15) (16) .
In the peripheral blood of persistently infected people, EBV resides exclusively in IgD − memory B cells (17) . However, in tonsils, EBV is found not only in memory B cells but also in GC and IgD + resting B cells in which EBNA1, LMP1, and LMP2A are expressed (17, 18) . Thereby, EBV may use antigen-driven B-cell activation and differentiation in mucosal secondary lymphoid organs, particularly GC reactions, to establish persistent infection in the memory B-cell pool. Together with LMP1, which constitutively activates CD40 signaling (19, 20) , LMP2A may provide a survival advantage for EBV-infected B cells by modifying GC B-cell selection. However, B-lineage-specific expression of LMP1 inhibits GC formation (20) or causes B-cell ablation through immune surveillance (21) . LMP2A does not affect affinity maturation of B cells in GCs when expressed in B cells of a transgenic mouse line (22) . Constitutive expression in transgenic mice used in these previous studies may be inappropriate for studying the influence of infection-induced virus proteins on B-cell differentiation, particularly in GCs. To date, the impact of LMP2A on differentiation and selection of GC B cells is still controversial.
Significance
Epstein-Barr virus (EBV) is a human herpesvirus that establishes persistent infection of the B-cell compartment. EBV is associated with autoimmune diseases, including systemic lupus erythematosus (SLE). However, the molecular mechanisms by which EBV contributes to autoimmunity remain unclear. We used previously undescribed mouse models to study the role of EBV-encoded latent membrane protein 2A (LMP2A), which mimics B-cell receptor signaling. Interestingly, LMP2A not only enhanced B-cell survival but also upregulated the transcription factor zinc finger and bric-a-brac, tramtrack domain-containing protein 20 and promoted plasma cell differentiation. When expressed late in B-cell development, LMP2A also caused prominent features of SLE, including autoantibody production with kidney immune complex deposition. Our findings suggest that LMP2A has important roles in B-cell activation and differentiation and in the development of EBV-associated autoimmune diseases.
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To explore the possibility that LMP2A contributes to persistent EBV infection by modifying GC B-cell selection, we generated an experimental mouse system in which LMP2A is conditionally expressed in GC B cells, similar to LMP2A expression in EBVinfected human B cells. Using this system, we analyzed the effects of LMP2A expression on B-cell entry into and differentiation within GCs.
Results

LMP2A Expression in B Cells Results in B-Cell Hyperactivation and Impaired
Humoral Responses. To characterize the effects of LMP2A expression on humoral immune responses, we generated mice in which LMP2A was conditionally expressed in B cells. We produced two knockin mice, LMP2A STOP mice and control GFP STOP mice, into whose ROSA26 locus one of two cassettes was inserted (Fig. S1A ). LMP2A STOP mice received a cassette containing floxed neomycin phosphotransferase cDNA (NEO) with a stop codon, N-terminal HAtagged LMP2A, an internal ribosome entry site sequence (IRES), and monomeric enhanced GFP (mEGFP). GFP STOP mice received a cassette containing floxed NEO with a stop codon, an IRES, and mEGFP (Fig. S1A) Fig. S2A ), suggesting that LMP2A may affect only some BCR signals.
To assess the overall effect of LMP2A expression on humoral immune responses, LMP2A CD19 mice and GFP CD19 mice were immunized with (4-hydroxy-3-nitrophenyl) acetyl chicken gamma globulin (NP-CGG). In the initial phase of humoral immune responses, some antigen-committed B cells proliferate and differentiate into low-affinity antibody-secreting plasmablasts in the extrafollicular area, whereas others migrate to the follicle and start to form GCs. An enzyme-linked immunospot (ELISPOT) analysis demonstrated significant increases in number of antibody-secreting cells (ASCs), particularly IgM + cells in spleens of LMP2A CD19 mice 1 wk after immunization (Fig. S2B ), indicating that LMP2A promotes extrafollicular B-cell differentiation into plasma cells. Immunohistochemical analysis of spleen sections revealed defective GC formation in LMP2A CD19 mice (Fig. S2C ) and fewer GL7 + and peanut agglutinin (PNA)-binding GC B cells in LMP2A CD19 mice than in GFP CD19 mice 2 wk after immunization. (Fig. 1C) . Antigen-specific IgG1 antibody responses also were severely impaired in LMP2A CD19 mice, although IgM responses in these mice were either unaffected or augmented ( Fig. 1D and Fig. S2D ). These data indicate that constitutive LMP2A expression enhances the differentiation of antigen-committed B cells into ASCs but suppresses either GC B-cell expansion or entry into GCs. To determine more precisely how LMP2A expression affects GC B-cell differentiation, LMP2A STOP mice and GFP STOP mice were crossed with Aicda-Cre mice (23) . The Aicda locus, which encodes the enzyme activationinduced cytidine deaminase (AID), is activated selectively in GC B cells (24) . The resulting strains express LMP2A and GFP (LMP2A AID mice) or only GFP (GFP AID mice) upon activation of the Aicda locus. In these mice, most B cells were GFP − , although some splenic B cells were GFP + (Fig. S3A ). These GFP + B cells acquired LMP2A and GFP coexpression as a consequence of differentiation in the bone marrow, where a fraction of immature B cells express AID (25) . Small numbers of GFP + cells were observed in immature bone marrow B cells (Fig. S3B) (Fig. S4B ). As expected, in both groups of mice more than 85% of GC B cells expressed GFP (Fig. S4C ). The only difference detected between these two groups of mice was a slightly but significantly lower frequency of light-zone GC B cells in LMP2A AID mice than in GFP AID mice (Fig. S4D ). Following positive selection by follicular ; n = 4). IgG1 with affinity for NP was captured using NP 16 -BSA. The bar in each time point indicates the average. Error bars show the means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. dendritic cell (FDC)-presented antigen, light-zone GC B cells either reenter the dark zone for further cell division or leave the GC to differentiate into plasma cells or memory B cells (26 (Fig. S4E) .
Frequencies of Antigen-Specific B Cells and Serum Levels of AntigenSpecific Antibodies in LMP2A AID and GFP AID Mice. Despite morphologically normal GC formation and elevated plasma cells, the frequency of NP-binding B cells was significantly reduced in GCs of LMP2A AID mice (Fig. 2B) . Serum levels of NP-specific IgG1, particularly, high-affinity IgG1, also were significantly lower in LMP2A AID mice than in GFP AID mice, although the serum level of NP-specific IgM in LMP2A AID mice was comparable to that in GFP AID mice (Fig. S4F) . ELISPOT assays revealed that frequencies of NP-specific IgG1-secreting cells were significantly reduced in LMP2A AID mice 16 d after immunization, although the numbers of total IgM-secreting cells were elevated (Fig. 2C) . These results indicate that Aicda-Cre-dependent expression of LMP2A strongly inhibits antigen-specific antibody responses but not GC formation, while enhancing plasma cell differentiation. (Fig. S5A) . The resulting bone marrow chimeric mice were immunized with NP-CGG and then were analyzed for GC formation 2 wk after immunization. Almost equal numbers of LMP2A AID -derived and WT-derived GC B cells were detected in immunized LMP2A AID /WT chimeras (Fig. S5 B and C) . AID mice or GFP AID mice were sorted by FACS. The Ig heavy-chain V H 186.2 genes, which are preferentially used by high-affinity NP-specific B cells in C57BL/6 mice, were amplified by RT-PCR, and then PCR direct sequencing was performed (27) (28) (29) (30) . As shown in Table S1 , the use of the V H 186.2 gene segment in NP-binding B cells was more than 2.5-fold lower in LMP2A AID mice than in GFP AID mice. However, the replacement mutation/silent mutation (R/S) ratio of complementaritydetermining regions (CDR) 1 and 2, the frequency of DFL16.1 use, the frequency of YYGS sequence insertion in CDR3, and the frequency of W-to-L mutation in CDR1 in V H 186. (Fig. 3A) . Furthermore, significantly higher levels of interferon regulatory factor 4 (Irf4) and B lymphocyte-induced maturation protein 1 (Blimp1) mRNAs, which encode key transcription factors involved in plasma cell differentiation, were induced in LMP2A CD19 B cells before Ig secretion. Nonetheless, Irf4 and Blimp1 mRNAs levels were lower in LMP2A CD19 B cells than in control B cells before stimulation (Fig. 3B ). CD138 staining, in combination with a dye-dilution assay, also revealed a higher frequency of CD138 + cells in LMP2A AID B cells after several cell divisions (Fig. 3C ). These in vitro findings suggest that LMP2A accelerates the differentiation of B cells into antibody-forming cells, which may explain the increased numbers of plasma cells and ASCs in spleens of immunized LMP2A AID mice.
LMP2A Expression in GC B Cells Leads to Autoantibody Production
and Development of Glomerulonephritis. It has been suggested that impaired affinity maturation in GCs may lead to autoantibody production (31) . EBV titers have been reported to correlate with disease activity in patients with systemic lupus erythematosus (32) (33) (34) (35) (36) , suggesting a possible involvement of EBV infection in autoantibody production. Indeed, we detected anti-dsDNA antibodies only in sera of LMP2A AID mice (Fig. 4A) . Anti-cardiolipin was analyzed by ELISPOT assay (n = 5). Sixteen days after immunization, splenocytes were prepared from either LMP2A AID or GFP AID mice and used for the assay. Error bars show the means ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not statistically significant.
antibodies also were detected in sera of LMP2A AID mice and, to a lesser extent, in sera of LMP2A CD19 mice (Fig. 4B) . Staining of kidney sections from either 6-mo-old unimmunized LMP2A AID mice or GFP AID mice with H&E or anti-IgG and IgM revealed subendothelial deposition of antibodies and development of glomerulonephritis-like lesions in LMP2A AID mice (Fig. 4C ). (Fig. 5A and Table S2 ). Consistent with this result, quantitative PCR (qPCR) showed significantly increased Zbtb20 and Trim12a transcript levels in LMP2A CD19 B cells (P = 0.01 and P < 0.0001, respectively) (Fig.  5B ). Zbtb20 encodes a zinc finger protein that has been shown to be important for B-cell differentiation into ASCs and for plasma cell longevity (37, 38) . Therefore, the induction of Zbtb20 expression by LMP2A in B cells may at contribute, at least in part, to the observed LMP2A effects on B-cell differentiation into antibody-secreting plasma cells.
LMP2A Expression Induced Epigenetic Changes in B Cells
Pathways Affected by LMP2A-Induced Epigenetic Changes. In contrast to the limited number of sites that were positively affected by LMP2A, we observed a generally repressive role of LMP2A on global histone modifications. Most sites that differed between LMP2A CD19 B cells and GFP CD19 B cells were repressed in LMP2A CD19 B cells, with ≥1.5-fold decreased H3K27ac ChIPseq signal at more than 300 sites. The top 300 loci that differed in H3K27ac, H3k4me1, or H3K4me3 signals between LMP2A CD19 B cells and GFP CD19 B cells were analyzed further for pathway enrichment. H3K27ac, H3K4me1, and H3K4me3 sites affected by LMP2A expression were linked to their nearest genes. IntPath analysis (39) of genes with decreased H3K27ac signal found enrichment for the TNFα/NF-κB pathway. Genes with decreased H3K4me1 signal were enriched for B-cell receptor signaling pathway and apoptosis (Table S3 ).
Discussion
In this study, we analyzed the effects of conditional expression of LMP2A on B-cell functions and humoral immune responses. LMP2A constitutively activates Syk in vitro and transduces BCRlike signals in vitro and in vivo (5, 10, 11) . Indeed, in B cells derived from LMP2A CD19 mice, LMP2A enhanced Syk tyrosine phosphorylation and B-cell proliferation in response to BCR stimulation, further supporting the existence of crosstalk between LMP2A and BCR signals. Moreover, B cells from both LMP2A CD19 and LMP2A AID mice displayed significantly accelerated in vitro differentiation into ASCs when stimulated with anti-CD40 antibody or sCD40L in combination with IL-4. These results are consistent with the reports that LMP2A expression facilitates plasma cell differentiation in vitro and in vivo in response to CD40 stimulation or Toll-like receptor agonists (40, 41) . These findings strongly suggest that LMP2A affects BCR signals as well as CD40 signals. AID -derived B cells had the ability to expand and survive in GCs and that this ability was comparable to that of normal B cells, even though they expressed mostly low-affinity BCR. This selection and survival advantage of LMP2A AID -derived low-affinity B cells could be attributed to LMP2A-mediated enhancement of BCR signals. It also is noteworthy that increased numbers of plasma cells and IgMsecreting cells, detected by flow cytometry and ELISPOT, respectively, were observed in LMP2A AID mice 2 wk after immunization, whereas the frequencies of antigen-specific cells in total IgM-and IgG1-secreting cells were decreased compared with those of immunized control mice. This finding is consistent with LMP2A-mediated enhancement of in vitro plasma cell differentiation and suggests that LMP2A may accelerate the differentiation of GC B cells into plasma cells, even before affinities of antibodies mature sufficiently, leading to the reduction in highaffinity antibody-producing B cells in LMP2A AID mice. Numbers of ASCs were significantly higher in LMP2A CD19 mice than in GFP CD19 mice 1 wk after immunization, and LMP2A expression suppressed subsequent GC formation. These observations suggest that LMP2A expression from an early stage of B-cell development may skew the fate of B-cell development. In this context, LMP2A may shift early B-cell-lineage cells from being antigen-committed in the initial phase of the immune response (42) toward extrafollicular plasma cell differentiation. Interestingly, in the acute phase of infectious mononucleosis (IM), 70-80% of circulating EBV-infected B cells differentiate toward plasmacytoid cells (43) . Also of note, in patients with IM, EBV-infected B cells are preferentially located in the extrafollicular area of lymphoid tissues, and some exhibit a plasmacytoid phenotype and express the replication-associated protein BZLF (44) . Our results suggest that LMP2A may have important roles in establishing these B-cell phenotypes.
Although LMP2A expression had limited effect on the epigenetic landscape, we observed robust up-regulation of Irf4 and Zbtb20 expression in LMP2A-expressing B cells. Zbtb20 was up-regulated at the mRNA level by approximately eightfold.
Interestingly, IRF4 binds to the Zbtb20 promoter and up-regulates Zbtb20 expression (37, 38) . Thus, LMP2A-and IRF4-mediated up-regulation of Zbtb20 may be an important mechanism by which EBV promotes plasma cell survival. Recent studies revealed that Zbtb20, which is a Bcl6 homolog and a member of the broad complex BTB zinc finger family, is a transcriptional repressor that has critical roles in plasma cell differentiation and survival (37, 45) . Zbtb20 is physiologically expressed in B1 and GC B cells, with highest expression in long-lived bone marrow ASCs (37) . Zbtb20 enhances primary B-cell terminal differentiation into ASCs and enhances plasma cell survival in a B-cell-intrinsic manner (45) . Interestingly, MCL1 levels are reduced in Zbtb20-deficient plasma cells relative to WT controls, suggesting a key Zbtb20 antiapoptotic role. Taken together, our findings suggest that LMP2A may be an important viral factor that enhances plasmacytoid differentiation of EBV-infected B cells, which can trigger the viral replication program.
LMP2A robustly induced Trim12a expression in B cells. TRIM12a is a member of the tripartite motif family, which contains RING, B-box, and coiled coil domains. Although Trim12a function remains largely uncharacterized, it is notable that Trim12 was previously implicated as a candidate gene in defective T-cellnegative selection in the nonobese diabetic (NOD) mouse strain (46) . TRIM12 expression was reduced by ∼300-fold in NOD thymocytes relative to controls. A major objective of future research will be to characterize further how TRIM12a may underlie LMP2A effects on B-cell development.
Despite these effects on Zbtb20 and Trim12a, most LMP2A effects on the B-cell epigenetic landscape suggested that LMP2a represses many B-cell loci. Consistent with this observation, LMP2A coexpression reversed LMP1-induced B-cell hyperactivation phenotypes in a murine model (22) . Pathways suppressed by LMP2A expression included apoptosis, Toll-like receptor signaling, B-cell receptor signaling, and the TNFα/ NF-κB pathway (Table S3) . Does LMP2A activate signaling molecules downstream of BCR signals? We also performed microarray analysis to determine the change in gene expression by LMP2A in B cells. We found marked similarities in the gene-expression profiles of LMP2A-and BCR-activated B cells (Fig. S6) (47) . However, quantitative analysis of these gene expressions will be required to confirm these possibilities. LMP2A AID mice produced autoantibodies against dsDNA and cardiolipin and had detectable immune complex deposition in the kidney; LMP2A CD19 mice also produced anti-cardiolipin antibodies. EBV titers correlate with systemic lupus erythematosus disease activity in some patients (32) (33) (34) (35) (36) . Both LMP2A CD19 and LMP2A AID mice exhibited hyperimmunoglobulinemia (Fig. S7 ), which often is associated with autoantibody production in murine autoimmunity models (31, 48) . Likewise, autoantibody production often is observed in IM patients (49, 50) . We speculate that LMP2A may have an important role in the generation of selfreactive B cells by enabling EBV-infected B cells to bypass GC selection. Interestingly, EBV-infected memory B cells obtained from IM patients express lower levels of self-reactive antibodies than EBV-uninfected memory cells (51) . Therefore, additional mechanisms may shape the repertoire of EBV-infected memory B cells, and LMP2A-mediated changes in GC B-cell selection may be particularly important for the generation of low-affinity antibodyproducing plasma cells.
In summary, conditional LMP2A expression in mice reduced the stringency of B-cell selection in GCs and resulted in preferential generation of low-affinity antibody-producing cells, possibly by augmenting BCR signals. These data strongly support the hypothesis that LMP2A contributes to persistent EBV infection in memory B cells by providing a survival advantage to EBV-infected GC B cells. In addition, LMP2A accelerated plasma cell differentiation in vitro and in vivo through enhanced Zbtb20 expression. B cells was evaluated by RT-qPCR. Error bars show the means ± SEM. *P < 0.05; ****P < 0.0001.
